Asandeutertinib vs Limertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Asandeutertinib
Marketed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
Reported efficacy
Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)
Result source: NCT05146219
Limertinib
Marketed by Jiangsu Aosaikang Pharmaceutical and partners
NCT04143607 · Phase 3 · status unknown
The trial randomized 337 patients to limertinib or an active comparator (gefitinib) with full triple-blinding (patient, investigator, and outcomes assessor masked) using matching placebos, which minimizes bias. The primary endpoint, progression-free survival, is a hard clinical measure, and it was met with a large, clinically meaningful improvement in median PFS (20.7 vs 9.7 months), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT06982924 (registry estimate)
Reported efficacy
Median Progression Free Survival (PFS) (CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years): NCT04143607 (limertinib/ASK120067 vs gefitinib first-line trial), primary endpoint median PFS: limertinib 20.7 months vs gefitinib 9.7 months; HR 0.44 (met)
Result source: NCT04143607
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asandeutertinib | Limertinib |
|---|---|---|
| PFS, median | —Trial running · NCT05382728 | —Trial running · NCT07109531 |
| OS, median | —Trial running · NCT05382728 | —Trial running · NCT07109531 |
| ORR | —Trial running · NCT05382728 | —Trial running · NCT07109531 |
| Duration of response, median | —Trial running · NCT05382728 | —Trial running · NCT07109531 |
PFS, median
- Asandeutertinib
- —Trial running · NCT05382728
- Limertinib
- —Trial running · NCT07109531
OS, median
- Asandeutertinib
- —Trial running · NCT05382728
- Limertinib
- —Trial running · NCT07109531
ORR
- Asandeutertinib
- —Trial running · NCT05382728
- Limertinib
- —Trial running · NCT07109531
Duration of response, median
- Asandeutertinib
- —Trial running · NCT05382728
- Limertinib
- —Trial running · NCT07109531
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · Limertinib's landscape